SCHEMBL3531671

SCHEMBL3531671

Cc1cccc(NC(=O)Nc2ccc(-c3coc4c(-c5ccc6oc(C)nc6c5)cnc(N)c34)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.61
AURKB Q96GD4 6/20 0.61
FLT1 P17948 5/20 0.61
FLT3 P36888 5/20 0.61
KIT P10721 4/20 0.61
CSF1R P07333 4/20 0.61
FGFR1 P11362 4/20 0.61
RPS6KB1 P23443 4/20 0.61
FLT4 P35916 4/20 0.61
PRKD3 O94806 3/20 0.61
RET P07949 3/20 0.61
AXL P30530 3/20 0.61
IRAK1 P51617 3/20 0.61
NTRK3 Q16288 3/20 0.61
HIPK4 Q8NE63 3/20 0.61
CLK4 Q9HAZ1 3/20 0.61
PLK4 O00444 3/20 0.61
AURKA O14965 3/20 0.61
JAK2 O60674 3/20 0.61
ROCK2 O75116 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3526116 0.85 KDR (0.67) KDRAURKBFLT1FLT3KIT
SCHEMBL3527807 0.85 KDR (0.58) KDRAURKBFLT1FLT3KIT
SCHEMBL3532946 0.85 KDR (0.69) KDRAURKBFLT1FLT3KIT
SCHEMBL3528701 0.84 KDR (0.68) KDRAURKBFLT1FLT3KIT
SCHEMBL3530956 0.83 FLT1 (0.77) KDRAURKBFLT1FLT3KIT
SCHEMBL3533520 0.82 KDR (0.63) KDRAURKBFLT1FLT3KIT
SCHEMBL3527107 0.82 KDR (0.63) KDRAURKBFLT1FLT3KIT
SCHEMBL3528557 0.82 KDR (0.63) KDRAURKBFLT1FLT3KIT
SCHEMBL3530386 0.82 KDR (0.59) KDRAURKBFLT1FLT3KIT
SCHEMBL3530752 0.82 KDR (0.59) KDRAURKBFLT1FLT3KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.